Verona Pharma announces new collaborations to develop dry powder and MDI formulations for COPD
This article was originally published here
Verona Pharma has announced new collaborations with two European technology companies to develop its first-in-class product candidate RPL554 as dry powder inhaler (DPI) and metered dose inhaler (MDI) formulations for maintenance treatment of chronic obstructive pulmonary disease (COPD).
Leave a Reply
Want to join the discussion?Feel free to contribute!